SAMN03290926
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.500
- COAGULATION+0.400
- COMPLEMENT+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.400
- INTERFERON_ALPHA_RESPONSE+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- XENOBIOTIC_METABOLISM+0.400
- APICAL_JUNCTION+0.300
- APICAL_SURFACE+0.300
Top 10 suppressed
- E2F_TARGETS-0.700
- G2M_CHECKPOINT-0.600
- MYC_TARGETS_V1-0.500
- MITOTIC_SPINDLE-0.300
- ANDROGEN_RESPONSE-0.200
- MYC_TARGETS_V2-0.200
- SPERMATOGENESIS-0.200
- UNFOLDED_PROTEIN_RESPONSE-0.200
- DNA_REPAIR-0.100
- OXIDATIVE_PHOSPHORYLATION-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_T55Y4Z0Y | low-grade glioma | — | 0.943 |
| 2 | 23849071-df2e-4421-b91d-90f66ec2c162 | — | — | 0.932 |
| 3 | BS_24AHZ9ZW | low-grade glioma | — | 0.922 |
| 4 | BS_4BWB0FA0 | low-grade glioma | — | 0.916 |
| 5 | BS_PQ6QEVE8 | Ganglioglioma | — | 0.902 |
| 6 | MDT-AP-0384 | Med | Medulloblastoma | 0.901 |
| 7 | SAMN03290902 | — | — | 0.896 |
| 8 | BS_EFEZB0ZH | low-grade glioma | — | 0.896 |
| 9 | BS_478TN841 | Ganglioglioma | — | 0.895 |
| 10 | SRR1431345 | GTEX | — | 0.894 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.400 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |